Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models.

Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ.

Mol Cancer Ther. 2019 Oct 9. pii: molcanther.0414.2019. doi: 10.1158/1535-7163.MCT-19-0414. [Epub ahead of print]

PMID:
31597714
2.

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.

Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaax0720. doi: 10.1126/scitranslmed.aax0720.

PMID:
31578241
3.

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.

Huang ZR, Tipparaju SK, Kirpotin DB, Pien C, Kornaga T, Noble CO, Koshkaryev A, Tran J, Kamoun WS, Drummond DC.

J Control Release. 2019 Sep 28;310:47-57. doi: 10.1016/j.jconrel.2019.08.006. Epub 2019 Aug 7.

PMID:
31400383
4.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.

Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC.

Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5.

PMID:
30952988
5.

Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway.

Alkan O, Schoeberl B, Shah M, Koshkaryev A, Heinemann T, Drummond DC, Yaffe MB, Raue A.

Sci Signal. 2018 Jul 24;11(540). pii: eaat0229. doi: 10.1126/scisignal.aat0229.

PMID:
30042127
6.

Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma.

Sawant RR, Jhaveri AM, Koshkaryev A, Zhu L, Qureshi F, Torchilin VP.

Mol Pharm. 2014 Feb 3;11(2):375-81. doi: 10.1021/mp300633f. Epub 2013 Dec 19.

PMID:
24325630
7.

Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.

Apte A, Koren E, Koshkaryev A, Torchilin VP.

Cancer Biol Ther. 2014 Jan;15(1):69-80. doi: 10.4161/cbt.26609. Epub 2013 Oct 21.

8.

The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy.

Sawant RR, Jhaveri AM, Koshkaryev A, Qureshi F, Torchilin VP.

J Drug Target. 2013 Aug;21(7):630-8. doi: 10.3109/1061186X.2013.789032. Epub 2013 Apr 17.

PMID:
23594094
9.

Efficient down-regulation of PKC-α gene expression in A549 lung cancer cells mediated by antisense oligodeoxynucleotides in dendrosomes.

Movassaghian S, Moghimi HR, Shirazi FH, Koshkaryev A, Trivedi MS, Torchilin VP.

Int J Pharm. 2013 Jan 30;441(1-2):82-91. doi: 10.1016/j.ijpharm.2012.12.015. Epub 2012 Dec 20.

PMID:
23262426
10.

Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.

Thekkedath R, Koshkaryev A, Torchilin VP.

Nanomedicine (Lond). 2013 Jul;8(7):1055-65. doi: 10.2217/nnm.12.138. Epub 2012 Dec 2.

11.

Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Koshkaryev A, Sawant R, Deshpande M, Torchilin V.

Adv Drug Deliv Rev. 2013 Jan;65(1):24-35. doi: 10.1016/j.addr.2012.08.009. Epub 2012 Sep 3. Review.

12.

Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition.

Koshkaryev A, Piroyan A, Torchilin VP.

Cancer Lett. 2013 Jul 1;334(2):293-301. doi: 10.1016/j.canlet.2012.06.008. Epub 2012 Jun 25.

13.

Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes.

Koshkaryev A, Piroyan A, Torchilin VP.

Cancer Biol Ther. 2012 Jan 1;13(1):50-60. doi: 10.4161/cbt.13.1.18871.

14.

Screening and optimization of ligand conjugates for lysosomal targeting.

Meerovich I, Koshkaryev A, Thekkedath R, Torchilin VP.

Bioconjug Chem. 2011 Nov 16;22(11):2271-82. doi: 10.1021/bc200336j. Epub 2011 Oct 6.

15.

Kinetic and thermodynamic approaches to the drug targeting phenomena.

Meerovich I, Koshkaryev A, Torchilin VP.

Curr Drug Discov Technol. 2011 Dec 1;8(4):287-300. Review.

PMID:
21726187
16.

Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting.

Biswas S, Dodwadkar NS, Sawant RR, Koshkaryev A, Torchilin VP.

J Drug Target. 2011 Aug;19(7):552-61. doi: 10.3109/1061186X.2010.536983. Epub 2011 Feb 25.

17.

Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B.

Koshkaryev A, Thekkedath R, Pagano C, Meerovich I, Torchilin VP.

J Drug Target. 2011 Sep;19(8):606-14. doi: 10.3109/1061186X.2010.550921. Epub 2011 Jan 29.

18.

Vitamin E induces phosphatidylserine externalization and red cell adhesion to endothelial cells.

Koshkaryev A, Barshtein G, Yedgar S.

Cell Biochem Biophys. 2010 Apr;56(2-3):109-14. doi: 10.1007/s12013-009-9074-3.

PMID:
20020330
19.

Rejuvenation treatment of stored red blood cells reverses storage-induced adhesion to vascular endothelial cells.

Koshkaryev A, Zelig O, Manny N, Yedgar S, Barshtein G.

Transfusion. 2009 Oct;49(10):2136-43. doi: 10.1111/j.1537-2995.2009.02251.x. Epub 2009 Jun 15.

PMID:
19538542
20.

Additive effect of red blood cell rigidity and adherence to endothelial cells in inducing vascular resistance.

Kaul DK, Koshkaryev A, Artmann G, Barshtein G, Yedgar S.

Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1788-93. doi: 10.1152/ajpheart.253.2008. Epub 2008 Aug 29.

21.

Phenylhydrazine as a partial model for beta-thalassaemia red blood cell hemodynamic properties.

Ramot Y, Koshkaryev A, Goldfarb A, Yedgar S, Barshtein G.

Br J Haematol. 2008 Mar;140(6):692-700. doi: 10.1111/j.1365-2141.2007.06976.x.

PMID:
18302715
22.

Blood banking-induced alteration of red blood cell flow properties.

Relevy H, Koshkaryev A, Manny N, Yedgar S, Barshtein G.

Transfusion. 2008 Jan;48(1):136-46. Epub 2007 Sep 27.

PMID:
17900281
23.

The red blood cell in vascular occlusion.

Yedgar S, Koshkaryev A, Barshtein G.

Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):263-8. Review.

24.

2-Butoxyethanol enhances the adherence of red blood cells.

Koshkaryev A, Barshtein G, Nyska A, Ezov N, Levin-Harrus T, Shabat S, Nyska M, Redlich M, Tsipis F, Yedgar S.

Arch Toxicol. 2003 Aug;77(8):465-9. Epub 2003 May 20.

PMID:
12756519
25.

Acridine orange induces translocation of phosphatidylserine to red blood cell surface.

Koshkaryev A, Yedgar S, Relevy H, Fibach E, Barshtein G.

Am J Physiol Cell Physiol. 2003 Sep;285(3):C720-2. Epub 2003 May 7.

Supplemental Content

Loading ...
Support Center